Literature DB >> 8384655

Pathophysiological studies of neuromuscular function in subacute organophosphate poisoning induced by phosmet.

J L Good1, R K Khurana, R F Mayer, W M Cintra, E X Albuquerque.   

Abstract

A 51 year old man developed progressive cranial and proximal muscle weakness, hyperreflexia and mental change. The disorder progressed over 9 days following the fifth weekly spraying with the organophosphate (OP) insecticide, phosmet, with limited symptoms of acute toxicity. Marked decremental responses of 50-80% on slow and fast rates of stimulation were improved to 15% by edrophonium or neostigmine. Intracellular recordings at the endplate region of intercostal muscle revealed small miniature endplate potentials (mepps), reduced mean acetylcholine sensitivity and normal membrane potentials. Electronmicroscopy revealed degeneration and regeneration of the endplates. This study demonstrates that OP poisoning due to phosmet can produce a subacute postsynaptic neuromuscular syndrome without marked symptoms of acute toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384655      PMCID: PMC1014864          DOI: 10.1136/jnnp.56.3.290

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis.

Authors:  E X Albuquerque; J E Rash; R F Mayer; J R Satterfield
Journal:  Exp Neurol       Date:  1976-06       Impact factor: 5.330

2.  Neostigmine-induced alterations at the mammalian neuromuscular junction. I. Muscle contraction and electrophysiology.

Authors:  T N Tiedt; E X Albuquerque; C S Hudson; J E Rash
Journal:  J Pharmacol Exp Ther       Date:  1978-05       Impact factor: 4.030

3.  The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. I. Agonist, desensitizing, and binding properties.

Authors:  G J Pascuzzo; A Akaike; M A Maleque; K P Shaw; R S Aronstam; D L Rickett; E X Albuquerque
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

4.  Neostigmine-induced alterations at the mammalian neuromuscular junction. II. Ultrastructure.

Authors:  C S Hudson; J E Rash; T N Tiedt; E X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  1978-05       Impact factor: 4.030

5.  Delayed neurotoxicity produced by an organophosphorus compound (Sumithion). A case report.

Authors:  T Sakamoto; Y Sawada; K Nishide; D Sadamitsu; T Yoshioka; T Sugimoto; S Nishii; H Kishi
Journal:  Arch Toxicol       Date:  1984-12       Impact factor: 5.153

6.  End-plate currents and acetylcholine noise at normal and myasthenic human end-plates.

Authors:  S G Cull-Candy; R Miledi; A Trautmann
Journal:  J Physiol       Date:  1979-02       Impact factor: 5.182

7.  Neurological manifestations of organophosphorous insecticide poisoning.

Authors:  R S Wadia; C Sadagopan; R B Amin; H V Sardesai
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-07       Impact factor: 10.154

8.  Edrophonium: an aid in the diagnosis of acute organophosphate poisoning.

Authors:  R Maselli; J H Jacobsen; J P Spire
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

9.  A comparative study of guanine N7-alkylation in mice in vivo by the organophosphorus insecticides trichlorphon, dimethoate, phosmet and bromophos.

Authors:  W Dedek; R Grahl; R Schmidt
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1984-08

10.  Agonist-induced myopathy at the neuromuscular junction is mediated by calcium.

Authors:  J P Leonard; M M Salpeter
Journal:  J Cell Biol       Date:  1979-09       Impact factor: 10.539

View more
  1 in total

1.  Prospective Hospital-Based Clinical and Electrophysiological Evaluation of Acute Organophosphate Poisoning.

Authors:  Karkal Ravishankar Naik; Aralikatte Onkarappa Saroja; Nagabushan Hesarur; Rekha Satish Patil
Journal:  Ann Indian Acad Neurol       Date:  2019 Jan-Mar       Impact factor: 1.383

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.